Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma

Abstract There is no recognized serum biomarker to predict the recurrence of endometrial carcinoma (EC). We aimed to explore serum human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) as the biomarkers to predict and monitor recurrence of type II EC. 191 patients diagnosed with type II EC...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Quan Quan, Qianqian Liao, Wanchun Yin, Shuwei Zhou, Sainan Gong, Xiaoling Mu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/689f3bf0919449cda19cfc08390a1656
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:689f3bf0919449cda19cfc08390a1656
record_format	dspace
spelling	oai:doaj.org-article:689f3bf0919449cda19cfc08390a16562021-11-08T10:47:41ZSerum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma10.1038/s41598-021-01263-w2045-2322https://doaj.org/article/689f3bf0919449cda19cfc08390a16562021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01263-whttps://doaj.org/toc/2045-2322Abstract There is no recognized serum biomarker to predict the recurrence of endometrial carcinoma (EC). We aimed to explore serum human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) as the biomarkers to predict and monitor recurrence of type II EC. 191 patients diagnosed with type II EC were involved for this retrospective study. Comparing recurrent with non-recurrent patients, HE4 levels resulted a statistically significant difference at primary diagnosis and recurrence, respectively (P = 0.002 and P = < 0.001), while CA125 levels resulted statistically significant (P = < 0.001) at recurrence. According to receiver operating characteristic curve analysis, the areas under the curve were significant for HE4 levels at primary diagnosis and recurrence predicting recurrence. Furthermore, CA125 levels at recurrence were significant. And the combination of both markers showed the higher sensitivity and specificity than single one. Patients with higher HE4 levels were associated with worse disease-free survival and overall survival, the opposite was true for patients with lower HE4 levels. The preoperative HE4 levels could be used to evaluate the risk factors of type II EC. Which suggested that HE4 levels might associated with the prognosis of type II EC. And combination of HE4 and CA125 could be applied to monitor recurrence during follow-up.Quan QuanQianqian LiaoWanchun YinShuwei ZhouSainan GongXiaoling MuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Quan Quan Qianqian Liao Wanchun Yin Shuwei Zhou Sainan Gong Xiaoling Mu Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma
description	Abstract There is no recognized serum biomarker to predict the recurrence of endometrial carcinoma (EC). We aimed to explore serum human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) as the biomarkers to predict and monitor recurrence of type II EC. 191 patients diagnosed with type II EC were involved for this retrospective study. Comparing recurrent with non-recurrent patients, HE4 levels resulted a statistically significant difference at primary diagnosis and recurrence, respectively (P = 0.002 and P = < 0.001), while CA125 levels resulted statistically significant (P = < 0.001) at recurrence. According to receiver operating characteristic curve analysis, the areas under the curve were significant for HE4 levels at primary diagnosis and recurrence predicting recurrence. Furthermore, CA125 levels at recurrence were significant. And the combination of both markers showed the higher sensitivity and specificity than single one. Patients with higher HE4 levels were associated with worse disease-free survival and overall survival, the opposite was true for patients with lower HE4 levels. The preoperative HE4 levels could be used to evaluate the risk factors of type II EC. Which suggested that HE4 levels might associated with the prognosis of type II EC. And combination of HE4 and CA125 could be applied to monitor recurrence during follow-up.
format	article
author	Quan Quan Qianqian Liao Wanchun Yin Shuwei Zhou Sainan Gong Xiaoling Mu
author_facet	Quan Quan Qianqian Liao Wanchun Yin Shuwei Zhou Sainan Gong Xiaoling Mu
author_sort	Quan Quan
title	Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma
title_short	Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma
title_full	Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma
title_fullStr	Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma
title_full_unstemmed	Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma
title_sort	serum he4 and ca125 combined to predict and monitor recurrence of type ii endometrial carcinoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/689f3bf0919449cda19cfc08390a1656
work_keys_str_mv	AT quanquan serumhe4andca125combinedtopredictandmonitorrecurrenceoftypeiiendometrialcarcinoma AT qianqianliao serumhe4andca125combinedtopredictandmonitorrecurrenceoftypeiiendometrialcarcinoma AT wanchunyin serumhe4andca125combinedtopredictandmonitorrecurrenceoftypeiiendometrialcarcinoma AT shuweizhou serumhe4andca125combinedtopredictandmonitorrecurrenceoftypeiiendometrialcarcinoma AT sainangong serumhe4andca125combinedtopredictandmonitorrecurrenceoftypeiiendometrialcarcinoma AT xiaolingmu serumhe4andca125combinedtopredictandmonitorrecurrenceoftypeiiendometrialcarcinoma
_version_	1718442624340197376

Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma

Ejemplares similares